XTL Biopharmaceuticals (XTLB) Short Interest Ratio & Short Volume → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free XTLB Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock AnalysisCompetitorsEarningsHeadlinesShort InterestSocial MediaStock AnalysisCompetitorsEarningsHeadlinesShort InterestSocial Media XTL Biopharmaceuticals Short Interest DataCurrent Short Volume22,400 sharesPrevious Short Volume60,200 sharesChange Vs. Previous Month-62.79%Dollar Volume Sold Short$57,792.00Short Interest Ratio / Days to Cover0.0Last Record DateApril 30, 2024Outstanding Shares5,450,000 sharesPercentage of Shares Shorted0.41%Today's Trading Volume18,984 sharesAverage Trading Volume15,743 sharesToday's Volume Vs. Average121% Short Selling XTL Biopharmaceuticals ? Sign up to receive the latest short interest report for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatXTLB Short Interest Over TimeXTLB Days to Cover Over TimeXTLB Percentage of Float Shorted Over Time Ad Weiss RatingsThis is the best new way to score with AIIf you thought that you missed your chance to score big on AI, I have great news. A rare second profit window is starting to open.Click now for the best way into the newest AI projects XTL Biopharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202422,400 shares $57,792.00 -62.8%N/A0 $2.58 4/15/202460,200 shares $161,336.00 -86.2%N/A0.1 $2.68 3/31/2024437,200 shares $1.23 million +21,760.0%N/A0.6 $2.81 3/15/20242,000 shares $1,760.00 +11.1%N/A0 $0.88 2/29/20241,800 shares $1,531.26 -37.9%N/A0.6 $0.85 2/15/20242,900 shares $2,608.26 -42.0%N/A0.9 $0.90 Get the Latest News and Ratings for XTLB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/20245,000 shares $4,378.50 -27.5%N/A1.4 $0.88 1/15/20246,900 shares $6,009.90 +1.5%N/A1.9 $0.87 12/31/20236,800 shares $6,868.68 -32.7%N/A1.7 $1.01 12/15/202310,100 shares $9,965.67 -15.8%N/A3.9 $0.99 11/30/202312,000 shares $12,360.00 +36.4%N/A5.7 $1.03 11/15/20238,800 shares $6,864.00 -24.8%N/A2.7 $0.78 10/31/202311,700 shares $10,148.58 +62.5%N/A3.2 $0.87 10/15/20237,200 shares $6,480.00 -22.6%N/A1.3 $0.90 9/30/20239,300 shares $8,347.68 -3.1%N/A1.7 $0.90 9/15/20239,600 shares $9,311.04 +29.7%N/A1.5 $0.97 8/31/20237,400 shares $7,770.00 +236.4%N/A0.5 $1.05 8/15/20232,200 shares $2,086.26 +29.4%N/A0.2 $0.95 7/31/20231,700 shares $1,385.84 -19.1%N/A0.1 $0.82 7/15/20232,100 shares $2,142.00 -16.0%N/A0.1 $1.02 6/30/20232,500 shares $2,376.75 -28.6%N/A0.2 $0.95 6/15/20233,500 shares $4,620.00 -25.5%N/A0.2 $1.32 5/31/20234,700 shares $5,734.00 +27.0%N/A0.6 $1.22 5/15/20233,700 shares $4,477.00 +23.3%N/A0.5 $1.21 4/30/20233,000 shares $3,360.00 -55.2%N/A0.5 $1.12 4/15/20236,700 shares $8,241.00 -23.0%N/A1.7 $1.23 3/31/20238,700 shares $11,049.00 +117.5%N/A4.1 $1.27 3/15/20234,000 shares $4,920.00 +2.6%N/A1.6 $1.23 2/28/20233,900 shares $5,459.61 -7.1%N/A1.3 $1.40 2/15/20234,200 shares $5,586.00 -16.0%N/A1.5 $1.33 1/31/20235,000 shares $5,850.00 -12.3%N/A1.4 $1.17 1/15/20235,700 shares $7,866.00 +2,750.0%N/A1.7 $1.38 12/30/2022200 shares $242.00 -95.7%N/A0.1 $1.21 12/15/20224,700 shares $5,687.00 -6.0%N/A1 $1.21 11/30/20225,000 shares $6,650.00 +6.4%N/A1.2 $1.33 11/15/20224,700 shares $6,674.00 +261.5%N/A1 $1.42 10/31/20221,300 shares $1,677.00 -40.9%N/A0.3 $1.29 10/15/20222,200 shares $2,651.00 +83.3%N/A0.3 $1.21 9/30/20221,200 shares $1,332.00 -77.4%N/A0.2 $1.11 9/15/20225,300 shares $7,155.00 -22.1%N/A0.9 $1.35Exposed: 10 CENT Crypto to Explode May 20th? (Ad)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 XTLB Short Interest - Frequently Asked Questions What is XTL Biopharmaceuticals' current short interest? Short interest is the volume of XTL Biopharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 22,400 shares of XTLB short. Learn More on XTL Biopharmaceuticals' current short interest. Is XTL Biopharmaceuticals' short interest increasing or decreasing? XTL Biopharmaceuticals saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 22,400 shares, a drop of 62.8% from the previous total of 60,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does XTL Biopharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to XTL Biopharmaceuticals: FSD Pharma Inc. (1.00%), Pieris Pharmaceuticals, Inc. (1.12%), Edesa Biotech, Inc. (0.69%), RedHill Biopharma Ltd. (2.38%), Purple Biotech Ltd (1.18%), Kiora Pharmaceuticals, Inc. (0.56%), Tonix Pharmaceuticals Holding Corp. (1.89%), Eterna Therapeutics Inc. (1.15%), NeuroSense Therapeutics Ltd. (0.16%), Imunon, Inc. (3.95%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short XTL Biopharmaceuticals stock? Short selling XTLB is an investing strategy that aims to generate trading profit from XTL Biopharmaceuticals as its price is falling. XTLB shares are trading up $0.17 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against XTL Biopharmaceuticals? A short squeeze for XTL Biopharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of XTLB, which in turn drives the price of the stock up even further. How often is XTL Biopharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XTLB, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: FSD Pharma Short Squeeze Pieris Pharmaceuticals Short Squeeze Edesa Biotech Short Squeeze RedHill Biopharma Short Squeeze Purple Biotech Short Squeeze Kiora Pharmaceuticals Short Squeeze Tonix Pharmaceuticals Short Squeeze Eterna Therapeutics Short Squeeze NeuroSense Therapeutics Short Squeeze Imunon Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:XTLB) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperPharma Giant Makes Deal with a "Drug Smuggler"Behind the MarketsHow Biden has already won 2024Porter & Company